Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ZGNX - FDA rejects Zogenix application for Dravet med Fintepla


ZGNX - FDA rejects Zogenix application for Dravet med Fintepla

  • The FDA has issued a Refusal to File (RTF) letter to Zogenix (NASDAQ:ZGNX) related to its marketing application seeking approval for FINTEPLA (fenfluramine hydrochloride) for the treatment of seizures associated with a rare and severe form of epilepsy called Dravet syndrome.
  • More news on: Zogenix, Inc., Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: Zogenix Inc.
Stock Symbol: ZGNX
Market: NASDAQ
Website: zogenix.com

Menu

ZGNX ZGNX Quote ZGNX Short ZGNX News ZGNX Articles ZGNX Message Board
Get ZGNX Alerts

News, Short Squeeze, Breakout and More Instantly...